Pliant Therapeutics, Inc. (PLRX) Fair Value 2026

PLRX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.9 /10

32 fundamental signals · 2 models active

Value Trap Risk

WARN (46/100)

Quick Summary — As of 2026-08-28, Pliant Therapeutics, Inc. (PLRX) trades at $1.11, versus a $1.57 median fair value across its 2 active models — 41.8% above the current price. QOC: 4.9/10. Value Trap Risk: 46/100 (WARN). 2/13 models active.

Key Facts

Ticker
PLRX
Price
$1.11
Quality Score
4.9/10
Value Trap Risk
46/100
Models Active
2/13
Last Updated
Strength: PWERM suggests +109.8% upside with 28% confidence
Risk: Value Trap score of 46 suggests caution despite apparent undervaluation

Is Pliant Therapeutics, Inc. (PLRX) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Pliant Therapeutics, Inc. (PLRX) appears undervalued as of : the median of 2 independent fair value estimates is $1.57, 41.8% above the current price of $1.11. Estimates range from $0.82 to $2.33. PLRX scores 4.9/10 on fundamental quality and 46/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. PLRX’s +41.8% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Pliant Therapeutics, Inc. Stock in 2026? →

What Fair Value Does Each Model Give PLRX?

2 Intrinsic Value Models vs. Current Price ($1.11)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $0.82 -26.2%
Option-Based · Medium Conviction
 $2.33 +109.8%

All Models Active

All 2 models are displayed above.

What Is Pliant Therapeutics, Inc. (PLRX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Pliant Therapeutics, Inc. presents a highly debated valuation profile at its current price of $1.11. The median intrinsic value is estimated at $1.57 (+41.8% median upside), masking a wide model spread between the 1 bullish models and 1 bearish models. Model dispersion is worth noting: PWERM targets $2.33 (+109.8%), versus ML-RIV at $0.82 (-26.2%). This +136.0% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About PLRX?

2 of 13 models are currently active for PLRX. Of these, 1 model suggests upside while 1 model suggests overvaluation. Taken together, their median fair value for PLRX is $1.57 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does PLRX Rank in Biotechnology?

Among 625 Biotechnology stocks, PLRX ranks #352 by Quality of Company score. CirclFi's QOC score of 4.9/10 evaluates 32 fundamental signals. A score of 4.9 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotechnology enterprise businesses. For Pliant Therapeutics, Inc., metrics like R&D burn rate provide important context that general-purpose valuation models may underweight.

Is PLRX a Value Trap?

CirclFi's Value Trap algorithm assigns PLRX a score of 46/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Pliant Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Pliant Therapeutics, Inc. scores 4.9 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +136.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PLRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PLRX's 2 active models, average confidence is 38%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Pliant Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

PLYXPolaryx Therapeutics, Inc.QOC 4.9SMMTSummit Therapeutics Inc.QOC 4.9CRVSCorvus Pharmaceuticals, Inc.QOC 4.9PVCTProvectus Biopharmaceuticals, Inc.QOC 4.9FBLGFibroBiologics, Inc.QOC 4.9NGNENeurogene Inc.QOC 4.9AGTXAgentix Corp.QOC 4.2TLXTelix Pharmaceuticals LimitedQOC 7.2IVAInventiva S.A.QOC 5.6EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: PLYX · SMMT · CRVS · PVCT · FBLG · NGNE · AGTX · TLX · IVA · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to PLRX?

5 companies across all industries closest to PLRX’s Quality of Company score of 4.9/10.

AUSIAura Systems, Inc.QOC 4.9MRNOMurano Global Investments PlcQOC 4.9YHGJYunhong Green CTI Ltd.QOC 4.9PNYGPony Group Inc.QOC 4.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AUSI · MRNO · YHGJ · PNYG · NVDA

Where Does PLRX Sit in CirclFi's Biotechnology Rankings?

PLRX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Pliant Therapeutics, Inc.’s Valuation?

What is Pliant Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi puts Pliant Therapeutics, Inc. (PLRX)'s intrinsic value at $1.57 — the median of 2 independent model estimates as of 2026-08-28, ranging from $0.82 to $2.33. The Quality of Company score is 4.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PLRX overvalued or undervalued right now?

At $1.11, 1 of 2 active models suggest PLRX may be undervalued, while 1 indicate potential overvaluation. The median of all 2 fair value estimates is $1.57, 41.8% above the current price of $1.11 — a consensus view that PLRX is undervalued. The assessment depends on which methodology best fits Pliant Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.9 mean for PLRX?

Pliant Therapeutics, Inc.'s QOC of 4.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on PLRX?

CirclFi analyzes PLRX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is PLRX a value trap in 2026?

Pliant Therapeutics, Inc.'s Value Trap score is 46/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Pliant Therapeutics, Inc. (PLRX) has a median fair value of $1.57 — 41.8% above the current price of $1.11 — as of 2026-08-28.” Source: circlfi.com/stock/PLRX/ · Methodology
Primary sources for this PLRX valuation
  • Financial statements: Pliant Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001746473) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PLRX as of ; valuations recomputed .